{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:27:18Z","timestamp":1790936838976,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003107","name":"Bundesministerium f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019434","name":"NIHR Exeter Clinical Research Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014690","name":"Ministerium f\u00fcr Kultur und Wissenschaft des Landes Nordrhein-Westfalen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007885","name":"European Association for the Study of Diabetes","doi-asserted-by":"publisher","award":["EASD mentorship pogramme"],"award-info":[{"award-number":["EASD mentorship pogramme"]}],"id":[{"id":"10.13039\/501100007885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Early-Career Award (227070\/Z\/23\/Z)"],"award-info":[{"award-number":["Early-Career Award (227070\/Z\/23\/Z)"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018703","name":"HORIZON EUROPE European Innovation Council","doi-asserted-by":"publisher","award":["Intercept-T2D \/ 101095433"],"award-info":[{"award-number":["Intercept-T2D \/ 101095433"]}],"id":[{"id":"10.13039\/100018703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022535","name":"BERLIN-CHEMIE","doi-asserted-by":"publisher","award":["honoraria for biostatistical education (OK)"],"award-info":[{"award-number":["honoraria for biostatistical education (OK)"]}],"id":[{"id":"10.13039\/501100022535","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00125-026-06802-6","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:04:48Z","timestamp":1784995488000},"page":"2672-2684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type 2 diabetes subtypes for precision medicine: methodological challenges and alternative prediction-based approaches"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8363-7434","authenticated-orcid":false,"given":"Tim","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2050-093X","authenticated-orcid":false,"given":"Christian","family":"Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1014-9058","authenticated-orcid":false,"given":"Pedro","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-732X","authenticated-orcid":false,"given":"John M.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3301-5869","authenticated-orcid":false,"given":"Oliver","family":"Ku\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"Suppl 1","key":"6802_CR1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142025. Diabetes Care 48(Suppl 1):S27\u2013S49. https:\/\/doi.org\/10.2337\/dc25-S002","journal-title":"Diabetes Care"},{"issue":"7","key":"6802_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00125-019-4909-y","volume":"62","author":"ER Pearson","year":"2019","unstructured":"Pearson ER (2019) Type 2 diabetes: a multifaceted disease. Diabetologia 62(7):1107\u20131112. https:\/\/doi.org\/10.1007\/s00125-019-4909-y","journal-title":"Diabetologia"},{"issue":"5","key":"6802_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00125-017-4210-x","volume":"60","author":"MI McCarthy","year":"2017","unstructured":"McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793\u2013799. https:\/\/doi.org\/10.1007\/s00125-017-4210-x","journal-title":"Diabetologia"},{"issue":"9881","key":"6802_CR4","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/S0140-6736(12)62207-7","volume":"381","author":"EAM Gale","year":"2013","unstructured":"Gale EAM (2013) Is type 2 diabetes a category error? Lancet 381(9881):1956\u20131957. https:\/\/doi.org\/10.1016\/S0140-6736(12)62207-7","journal-title":"Lancet"},{"key":"6802_CR5","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2337\/dci22-0034","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65:1925\u20131966. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetologia"},{"issue":"1","key":"6802_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s43856-023-00360-3","volume":"3","author":"S Misra","year":"2023","unstructured":"Misra S, Wagner R, Ozkan B et al (2023) Precision subclassification of type 2 diabetes: a systematic review. Commun Med 3(1):138. https:\/\/doi.org\/10.1038\/s43856-023-00360-3","journal-title":"Commun Med"},{"key":"6802_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00125-020-05181-w","volume":"63","author":"WK Chung","year":"2020","unstructured":"Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63:1671\u20131693. https:\/\/doi.org\/10.1007\/s00125-020-05181-w","journal-title":"Diabetologia"},{"issue":"5","key":"6802_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/s2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, K\u00e4r\u00e4j\u00e4m\u00e4ki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361\u2013369. https:\/\/doi.org\/10.1016\/s2213-8587(18)30051-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"6802_CR9","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1007\/s00125-021-05625-x","volume":"65","author":"C Herder","year":"2022","unstructured":"Herder C, Roden M (2022) A novel diabetes typology: towards precision diabetology from pathogenesis to treatment. Diabetologia 65(11):1770\u20131781. https:\/\/doi.org\/10.1007\/s00125-021-05625-x","journal-title":"Diabetologia"},{"issue":"10","key":"6802_CR10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","volume":"29","author":"DK Tobias","year":"2023","unstructured":"Tobias DK, Merino J, Ahmad A et al (2023) Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med 29(10):2438\u20132457. https:\/\/doi.org\/10.1038\/s41591-023-02502-5","journal-title":"Nat Med"},{"issue":"6","key":"6802_CR11","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","volume":"27","author":"TM Wallace","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27(6):1487\u20131495. https:\/\/doi.org\/10.2337\/diacare.27.6.1487","journal-title":"Diabetes Care"},{"issue":"1","key":"6802_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S2213-8587(25)00283-9","volume":"14","author":"O Asplund","year":"2026","unstructured":"Asplund O, Thangam M, Prasad RB et al (2026) Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden. Lancet Diabetes Endocrinol 14(1):29\u201340. https:\/\/doi.org\/10.1016\/S2213-8587(25)00283-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"6802_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S2213-8587(23)00165-1","volume":"11","author":"PW Franks","year":"2023","unstructured":"Franks PW, Cefalu WT, Dennis J et al (2023) Precision medicine for cardiometabolic disease: a framework for clinical translation. Lancet Diabetes Endocrinol 11(11):822\u2013835. https:\/\/doi.org\/10.1016\/S2213-8587(23)00165-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6802_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684\u2013694. https:\/\/doi.org\/10.1016\/S2213-8587(19)30187-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6802_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S2213-8587(18)30316-4","volume":"7","author":"X Zou","year":"2019","unstructured":"Zou X, Zhou X, Zhu Z, Ji L (2019) Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol 7(1):9\u201311. https:\/\/doi.org\/10.1016\/S2213-8587(18)30316-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"6802_CR16","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/jcm9072083","volume":"9","author":"H Tanabe","year":"2020","unstructured":"Tanabe H, Saito H, Kudo A et al (2020) Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a Japanese retrospective cohort study. J Clin Med 9(7):2083. https:\/\/doi.org\/10.3390\/jcm9072083","journal-title":"J Clin Med"},{"issue":"9","key":"6802_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S2213-8587(23)00195-X","volume":"11","author":"JS Varghese","year":"2023","unstructured":"Varghese JS, Carrillo-Larco RM, Narayan KMV (2023) Achieving replicable subphenotypes of adult-onset diabetes. Lancet Diabetes Endocrinol 11(9):635\u2013636. https:\/\/doi.org\/10.1016\/S2213-8587(23)00195-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"6802_CR18","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.2337\/db20-1054","volume":"70","author":"C Herder","year":"2021","unstructured":"Herder C, Maalmi H, Strassburger K et al (2021) Differences in biomarkers of inflammation between novel subgroups of recent-onset diabetes. Diabetes 70(5):1198\u20131208. https:\/\/doi.org\/10.2337\/db20-1054","journal-title":"Diabetes"},{"issue":"6","key":"6802_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","volume":"7","author":"JM Dennis","year":"2019","unstructured":"Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7(6):442\u2013451. https:\/\/doi.org\/10.1016\/S2213-8587(19)30087-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6802_CR20","doi-asserted-by":"publisher","first-page":"e002731","DOI":"10.1136\/bmjdrc-2021-002731","volume":"10","author":"DH Christensen","year":"2022","unstructured":"Christensen DH, Nicolaisen SK, Ahlqvist E et al (2022) Type 2 diabetes classification: a data-driven cluster study of the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort. BMJ Open Diabetes Res Care 10(2):e002731. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002731","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"6802_CR21","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00125-021-05485-5","volume":"64","author":"M Lugner","year":"2021","unstructured":"Lugner M, Gudbj\u00f6rnsdottir S, Sattar N et al (2021) Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study. Diabetologia 64(9):1973\u20131981. https:\/\/doi.org\/10.1007\/s00125-021-05485-5","journal-title":"Diabetologia"},{"issue":"9","key":"6802_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1111\/dom.14063","volume":"22","author":"AR Kahkoska","year":"2020","unstructured":"Kahkoska AR, Geybels MS, Klein KR et al (2020) Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials. Diabetes Obes Metab 22(9):1537\u20131547. https:\/\/doi.org\/10.1111\/dom.14063","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"6802_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00125-026-06687-5","volume":"69","author":"Z Li","year":"2026","unstructured":"Li Z, Liu S, Ho JC, Narayan KMV, Ali MK, Varghese JS (2026) Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA. Diabetologia 69(6):1545\u20131556. https:\/\/doi.org\/10.1007\/s00125-026-06687-5","journal-title":"Diabetologia"},{"issue":"9","key":"6802_CR24","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1007\/s00125-021-05490-8","volume":"64","author":"RC Slieker","year":"2021","unstructured":"Slieker RC, Donnelly LA, Fitipaldi H et al (2021) Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia 64(9):1982\u20131989. https:\/\/doi.org\/10.1007\/s00125-021-05490-8","journal-title":"Diabetologia"},{"issue":"3","key":"6802_CR25","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1530\/joe-20-0596","volume":"252","author":"E Ahlqvist","year":"2022","unstructured":"Ahlqvist E, Prasad RB, Groop L (2022) 100 YEARS OF INSULIN: towards improved precision and a new classification of diabetes mellitus. J Endocrinol 252(3):R59\u2013R70. https:\/\/doi.org\/10.1530\/joe-20-0596","journal-title":"J Endocrinol"},{"issue":"6","key":"6802_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2213-8587(18)30124-4","volume":"6","author":"M Van Smeden","year":"2018","unstructured":"Van Smeden M, Harrell FE, Dahly DL (2018) Novel diabetes subgroups. Lancet Diabetes Endocrinol 6(6):439\u2013440. https:\/\/doi.org\/10.1016\/S2213-8587(18)30124-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6802_CR27","unstructured":"Hastie T, Tibshirani R, Friedman J (2009) Cluster analysis. In: The elements of statistical learning: data mining, inference, and prediction. Vol 2. Springer, New York, pp 501\u2013527"},{"issue":"6","key":"6802_CR28","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/ijop.13246","volume":"59","author":"E Toffalini","year":"2024","unstructured":"Toffalini E, Gambarota F, Perugini A et al (2024) Clusters that are not there: an R tutorial and a Shiny app to quantify a priori inferential risks when using clustering methods. Int J Psychol 59(6):1183\u20131198. https:\/\/doi.org\/10.1002\/ijop.13246","journal-title":"Int J Psychol"},{"issue":"11","key":"6802_CR29","doi-asserted-by":"publisher","first-page":"e0259372","DOI":"10.1371\/journal.pone.0259372","volume":"16","author":"Y Aoki","year":"2021","unstructured":"Aoki Y, Hamr\u00e9n B, Clegg LE et al (2021) Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR-TIMI 53 trial). PLoS One 16(11):e0259372. https:\/\/doi.org\/10.1371\/journal.pone.0259372","journal-title":"PLoS One"},{"issue":"14","key":"6802_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317\u20131326. https:\/\/doi.org\/10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"issue":"9","key":"6802_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S2213-8587(19)30257-8","volume":"7","author":"E Ahlqvist","year":"2019","unstructured":"Ahlqvist E, Tuomi T, Groop L (2019) Clusters provide a better holistic view of type 2 diabetes than simple clinical features. Lancet Diabetes Endocrinol 7(9):668\u2013669. https:\/\/doi.org\/10.1016\/S2213-8587(19)30257-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"48","key":"6802_CR32","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1093\/eurheartj\/ehae746","volume":"45","author":"PW Franks","year":"2024","unstructured":"Franks PW, Sargent JL (2024) Diabetes and obesity: leveraging heterogeneity for precision medicine. Eur Heart J 45(48):5146\u20135155. https:\/\/doi.org\/10.1093\/eurheartj\/ehae746","journal-title":"Eur Heart J"},{"issue":"11","key":"6802_CR33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S2213-8587(23)00159-6","volume":"11","author":"RD Leslie","year":"2023","unstructured":"Leslie RD, Ma RCW, Franks PW, Nadeau KJ, Pearson ER, Redondo MJ (2023) Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. Lancet Diabetes Endocrinol 11(11):848\u2013860. https:\/\/doi.org\/10.1016\/S2213-8587(23)00159-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6802_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41591-026-04309-6","volume":"32","author":"DE Coral","year":"2026","unstructured":"Coral DE, Sargent JL, Carrasco-Zanini J et al (2026) Five tenets for advancing evidence-based precision medicine. Nat Med 32(4):1211\u20131222. https:\/\/doi.org\/10.1038\/s41591-026-04309-6","journal-title":"Nat Med"},{"issue":"10","key":"6802_CR35","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00125-025-06486-4","volume":"68","author":"T Mori","year":"2025","unstructured":"Mori T, Zaharia OP, Stra\u00dfburger K et al (2025) Recognising, quantifying and accounting for classification uncertainty in type 2 diabetes subtypes. Diabetologia 68(10):2139\u20132150. https:\/\/doi.org\/10.1007\/s00125-025-06486-4","journal-title":"Diabetologia"},{"issue":"11","key":"6802_CR36","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s00125-024-06248-8","volume":"67","author":"H Tanabe","year":"2024","unstructured":"Tanabe H, Sato M, Miyake A et al (2024) Machine learning-based reproducible prediction of type 2 diabetes subtypes. Diabetologia 67(11):2446\u20132458. https:\/\/doi.org\/10.1007\/s00125-024-06248-8","journal-title":"Diabetologia"},{"issue":"1","key":"6802_CR37","doi-asserted-by":"publisher","first-page":"100477","DOI":"10.1016\/j.xcrm.2021.100477","volume":"3","author":"A Wesolowska-Andersen","year":"2022","unstructured":"Wesolowska-Andersen A, Brorsson CA, Bizzotto R et al (2022) Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: an IMI DIRECT study. Cell Rep Med 3(1):100477. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100477","journal-title":"Cell Rep Med"},{"issue":"6","key":"6802_CR38","doi-asserted-by":"publisher","first-page":"e004493","DOI":"10.1136\/bmjdrc-2024-004493","volume":"12","author":"VV Bjark\u00f8","year":"2024","unstructured":"Bjark\u00f8 VV, Haug EB, Langhammer A et al (2024) Clinical utility of novel diabetes subgroups in predicting vascular complications and mortality: up to 25 years of follow-up of the HUNT Study. BMJ Open Diabetes Res Care 12(6):e004493. https:\/\/doi.org\/10.1136\/bmjdrc-2024-004493","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"6802_CR39","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","volume":"24","author":"RM Conroy","year":"2003","unstructured":"Conroy RM, Py\u00f6r\u00e4l\u00e4 K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987\u20131003. https:\/\/doi.org\/10.1016\/S0195-668X(03)00114-3","journal-title":"Eur Heart J"},{"key":"6802_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000339789","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1\u2013138. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Kidney Int Suppl"},{"issue":"23","key":"6802_CR41","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23):2427\u20132443. https:\/\/doi.org\/10.1056\/NEJMoa066224","journal-title":"N Engl J Med"},{"issue":"9681","key":"6802_CR42","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125\u20132135. https:\/\/doi.org\/10.1016\/S0140-6736(09)60953-3","journal-title":"Lancet"},{"issue":"9","key":"6802_CR43","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00125-005-1869-1","volume":"48","author":"PD Home","year":"2005","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2005) Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 48(9):1726\u20131735. https:\/\/doi.org\/10.1007\/s00125-005-1869-1","journal-title":"Diabetologia"},{"issue":"1","key":"6802_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S2213-8587(25)00303-1","volume":"14","author":"M Roden","year":"2026","unstructured":"Roden M (2026) The long and winding road to precision diabetology. Lancet Diabetes Endocrinol 14(1):3\u20135. https:\/\/doi.org\/10.1016\/S2213-8587(25)00303-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"6802_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s42255-023-00943-3","volume":"6","author":"C Dwibedi","year":"2024","unstructured":"Dwibedi C, Ekstr\u00f6m O, Brandt J et al (2024) Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab 6(1):50\u201360. https:\/\/doi.org\/10.1038\/s42255-023-00943-3","journal-title":"Nat Metab"},{"key":"6802_CR46","doi-asserted-by":"publisher","first-page":"109067","DOI":"10.1016\/j.diabres.2021.109067","volume":"180","author":"H Tanabe","year":"2021","unstructured":"Tanabe H, Masuzaki H, Shimabukuro M (2021) Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: a perspective. Diabetes Res Clin Pract 180:109067. https:\/\/doi.org\/10.1016\/j.diabres.2021.109067","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"6802_CR47","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2337\/dbi20-0002","volume":"69","author":"JM Dennis","year":"2020","unstructured":"Dennis JM (2020) Precision medicine in type 2 diabetes: using individualized prediction models to optimize selection of treatment. Diabetes 69(10):2075\u20132085. https:\/\/doi.org\/10.2337\/dbi20-0002","journal-title":"Diabetes"},{"issue":"12","key":"6802_CR48","doi-asserted-by":"publisher","first-page":"e873","DOI":"10.1016\/S2589-7500(22)00174-1","volume":"4","author":"JM Dennis","year":"2022","unstructured":"Dennis JM, Young KG, McGovern AP et al (2022) Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digital Health 4(12):e873\u2013e883. https:\/\/doi.org\/10.1016\/S2589-7500(22)00174-1","journal-title":"Lancet Digital Health"},{"issue":"5","key":"6802_CR49","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s00125-024-06099-3","volume":"67","author":"P Cardoso","year":"2024","unstructured":"Cardoso P, Young KG, Nair AT et al (2024) Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia 67(5):822\u2013836. https:\/\/doi.org\/10.1007\/s00125-024-06099-3","journal-title":"Diabetologia"},{"issue":"1","key":"6802_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12911-023-02207-2","volume":"23","author":"A Venkatasubramaniam","year":"2023","unstructured":"Venkatasubramaniam A, Mateen BA, Shields BM et al (2023) Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. BMC Med Inform Decis Mak 23(1):110. https:\/\/doi.org\/10.1186\/s12911-023-02207-2","journal-title":"BMC Med Inform Decis Mak"},{"issue":"10480","key":"6802_CR51","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S0140-6736(24)02617-5","volume":"405","author":"JM Dennis","year":"2025","unstructured":"Dennis JM, Young KG, Cardoso P et al (2025) A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study. Lancet 405(10480):701\u2013714. https:\/\/doi.org\/10.1016\/S0140-6736(24)02617-5","journal-title":"Lancet"},{"issue":"2","key":"6802_CR52","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41591-022-02120-7","volume":"29","author":"BM Shields","year":"2023","unstructured":"Shields BM, Dennis JM, Angwin CD et al (2023) Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study. Nat Med 29(2):376\u2013383. https:\/\/doi.org\/10.1038\/s41591-022-02120-7","journal-title":"Nat Med"},{"issue":"10480","key":"6802_CR53","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(24)02844-7","volume":"405","author":"S Seidu","year":"2025","unstructured":"Seidu S, Ikhile D (2025) Personalised type 2 diabetes therapy in primary care. Lancet 405(10480):672\u2013674. https:\/\/doi.org\/10.1016\/S0140-6736(24)02844-7","journal-title":"Lancet"},{"key":"6802_CR54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1146\/annurev-statistics-042324-123749","volume":"13","author":"B Van Calster","year":"2026","unstructured":"Van Calster B, van Smeden M, van Amsterdam W, Coemans M, Wynants L, Steyerberg EW (2026) The enemies of reliable and useful clinical prediction models: a review of statistical and scientific challenges. Annu Rev Stat Appl 13:465\u2013492. https:\/\/doi.org\/10.1146\/annurev-statistics-042324-123749","journal-title":"Annu Rev Stat Appl"},{"issue":"12","key":"6802_CR55","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2589-7500(20)30200-4","volume":"2","author":"J Wilkinson","year":"2020","unstructured":"Wilkinson J, Arnold KF, Murray EJ et al (2020) Time to reality check the promises of machine learning-powered precision medicine. Lancet Digital Health 2(12):e677\u2013e680. https:\/\/doi.org\/10.1016\/S2589-7500(20)30200-4","journal-title":"Lancet Digital Health"},{"key":"6802_CR56","doi-asserted-by":"publisher","unstructured":"G\u00fcdemann LM, Young KG, Cardoso P et al (2026) Validation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study. Lancet Reg Health \u2013 Europe 61. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101547","DOI":"10.1016\/j.lanepe.2025.101547"},{"issue":"1","key":"6802_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12916-023-02779-w","volume":"21","author":"B Van Calster","year":"2023","unstructured":"Van Calster B, Steyerberg EW, Wynants L, van Smeden M (2023) There is no such thing as a validated prediction model. BMC Med 21(1):70. https:\/\/doi.org\/10.1186\/s12916-023-02779-w","journal-title":"BMC Med"},{"issue":"1","key":"6802_CR58","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","volume":"17","author":"B Van Calster","year":"2019","unstructured":"Van Calster B, McLernon DJ, van Smeden M et al (2019) Calibration: the Achilles heel of predictive analytics. BMC Med 17(1):230. https:\/\/doi.org\/10.1186\/s12916-019-1466-7","journal-title":"BMC Med"},{"issue":"6","key":"6802_CR59","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S2213-8587(18)30139-6","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Prasad RB, Tuomi T, Rosengren A, Groop L (2018) Novel diabetes subgroups - authors\u2019 reply. Lancet Diabetes Endocrinol 6(6):440\u2013441. https:\/\/doi.org\/10.1016\/S2213-8587(18)30139-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"6802_CR60","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.2337\/dc24-2023","volume":"48","author":"O-P Zaharia","year":"2025","unstructured":"Zaharia O-P, Kupriyanova Y, Bobrov P et al (2025) Role of adipose tissue compartments for cardiovascular risk in diabetes endotypes. Diabetes Care 48(12):2031\u20132035. https:\/\/doi.org\/10.2337\/dc24-2023","journal-title":"Diabetes Care"},{"issue":"11","key":"6802_CR61","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1007\/s00125-022-05769-4","volume":"65","author":"AJ Deutsch","year":"2022","unstructured":"Deutsch AJ, Ahlqvist E, Udler MS (2022) Phenotypic and genetic classification of diabetes. Diabetologia 65(11):1758\u20131769. https:\/\/doi.org\/10.1007\/s00125-022-05769-4","journal-title":"Diabetologia"},{"issue":"11","key":"6802_CR62","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s41588-021-00948-2","volume":"53","author":"D Mansour Aly","year":"2021","unstructured":"Mansour Aly D, Dwivedi OP, Prasad RB et al (2021) Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes. Nat Genet 53(11):1534\u20131542. https:\/\/doi.org\/10.1038\/s41588-021-00948-2","journal-title":"Nat Genet"},{"issue":"2","key":"6802_CR63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00592-024-02436-5","volume":"62","author":"T Mori","year":"2025","unstructured":"Mori T, Prystupa K, Stra\u00dfburger K et al (2025) A web-based application for diabetes subtyping: The DDZ Diabetes-Cluster-Tool. Acta Diabetol 62(2):281\u2013283. https:\/\/doi.org\/10.1007\/s00592-024-02436-5","journal-title":"Acta Diabetol"},{"issue":"1","key":"6802_CR64","doi-asserted-by":"publisher","first-page":"e001506","DOI":"10.1136\/bmjdrc-2020-001506","volume":"8","author":"RM Anjana","year":"2020","unstructured":"Anjana RM, Baskar V, Nair ATN et al (2020) Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Res Care 8(1):e001506. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001506","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"6802_CR65","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S2213-8587(19)30250-5","volume":"7","author":"JM Dennis","year":"2019","unstructured":"Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Clusters provide a better holistic view of type 2 diabetes than simple clinical features - authors\u2019 reply. Lancet Diabetes Endocrinol 7(9):669. https:\/\/doi.org\/10.1016\/S2213-8587(19)30250-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6802_CR66","doi-asserted-by":"crossref","unstructured":"Hastie T, Tibshirani R, Friedman J (2009) Unsupervised learning. In: The elements of statistical learning: data mining, inference, and prediction. Vol 2. Springer, New York, pp 485\u2013586","DOI":"10.1007\/978-0-387-84858-7_14"},{"issue":"28","key":"6802_CR67","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/eurheartj\/ehad260","volume":"44","author":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration","year":"2023","unstructured":"SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration (2023) SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 44(28):2544\u20132556. https:\/\/doi.org\/10.1093\/eurheartj\/ehad260","journal-title":"Eur Heart J"},{"issue":"1","key":"6802_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41591-020-1116-9","volume":"27","author":"R Wagner","year":"2021","unstructured":"Wagner R, Heni M, Tabak AG et al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27(1):49\u201357. https:\/\/doi.org\/10.1038\/s41591-020-1116-9","journal-title":"Nat Med"},{"issue":"2","key":"6802_CR69","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/dci25-0054","volume":"49","author":"R Wagner","year":"2026","unstructured":"Wagner R, Selvin E, Sehgal R et al (2026) Beyond glucose\u2014rethinking prediabetes for precision prevention. Diabetes Care 49(2):226\u2013235. https:\/\/doi.org\/10.2337\/dci25-0054","journal-title":"Diabetes Care"},{"issue":"1","key":"6802_CR70","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-025-02617-8","volume":"24","author":"M-T Huemer","year":"2025","unstructured":"Huemer M-T, Spagnuolo MC, Maalmi H et al (2025) Phenotype-based clusters, inflammation and cardiometabolic complications in older people before the diagnosis of type 2 diabetes: KORA F4\/FF4 cohort study. Cardiovasc Diabetol 24(1):83. https:\/\/doi.org\/10.1186\/s12933-025-02617-8","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"6802_CR71","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00125-006-0348-7","volume":"49","author":"EAM Gale","year":"2006","unstructured":"Gale EAM (2006) Declassifying diabetes. Diabetologia 49(9):1989\u20131995. https:\/\/doi.org\/10.1007\/s00125-006-0348-7","journal-title":"Diabetologia"},{"issue":"9","key":"6802_CR72","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00125-023-05951-2","volume":"66","author":"O Kuss","year":"2023","unstructured":"Kuss O, Opitz ME, Brandstetter LV, Schlesinger S, Roden M, Hoyer A (2023) How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials. Diabetologia 66(9):1622\u20131632. https:\/\/doi.org\/10.1007\/s00125-023-05951-2","journal-title":"Diabetologia"},{"issue":"1","key":"6802_CR73","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/cpt.1372","volume":"106","author":"JS Gewandter","year":"2019","unstructured":"Gewandter JS, McDermott MP, He H et al (2019) Demonstrating heterogeneity of treatment effects among patients: an overlooked but important step toward precision medicine. Clin Pharmacol Ther 106(1):204\u2013210. https:\/\/doi.org\/10.1002\/cpt.1372","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"6802_CR74","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.pain.2013.09.019","volume":"155","author":"RH Dworkin","year":"2014","unstructured":"Dworkin RH, McDermott MP, Farrar JT, O\u2019Connor AB, Senn S (2014) Interpreting patient treatment response in analgesic clinical trials: implications for genotyping, phenotyping, and personalized pain treatment. Pain 155(3):457\u2013460. https:\/\/doi.org\/10.1016\/j.pain.2013.09.019","journal-title":"Pain"},{"issue":"7","key":"6802_CR75","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/sim.6739","volume":"35","author":"S Senn","year":"2016","unstructured":"Senn S (2016) Mastering variation: variance components and personalised medicine. Stat Med 35(7):966\u2013977. https:\/\/doi.org\/10.1002\/sim.6739","journal-title":"Stat Med"},{"issue":"7733","key":"6802_CR76","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/d41586-018-07535-2","volume":"563","author":"S Senn","year":"2018","unstructured":"Senn S (2018) Statistical pitfalls of personalized medicine. Nature 563(7733):619\u2013621. https:\/\/doi.org\/10.1038\/d41586-018-07535-2","journal-title":"Nature"},{"issue":"7","key":"6802_CR77","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00592-024-02425-8","volume":"62","author":"O Kuss","year":"2024","unstructured":"Kuss O, Roden M, Schlesinger S, Hoyer A (2024) The potential of precision diabetology for type 2 diabetes treatment\u2014evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials. Acta Diabetol 62(7):1073\u20131080. https:\/\/doi.org\/10.1007\/s00592-024-02425-8","journal-title":"Acta Diabetol"},{"issue":"14","key":"6802_CR78","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jama.2023.3322","volume":"329","author":"J Sundstr\u00f6m","year":"2023","unstructured":"Sundstr\u00f6m J, Lind L, Nowrouzi S et al (2023) Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA 329(14):1160\u20131169. https:\/\/doi.org\/10.1001\/jama.2023.3322","journal-title":"JAMA"},{"issue":"11","key":"6802_CR79","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s00125-022-05782-7","volume":"65","author":"S Griffin","year":"2022","unstructured":"Griffin S (2022) Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time. Diabetologia 65(11):1913\u20131921. https:\/\/doi.org\/10.1007\/s00125-022-05782-7","journal-title":"Diabetologia"},{"issue":"7","key":"6802_CR80","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41591-024-03033-3","volume":"30","author":"SS Lim","year":"2024","unstructured":"Lim SS, Semnani-Azad Z, Morieri ML et al (2024) Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat Med 30(7):1874\u20131881. https:\/\/doi.org\/10.1038\/s41591-024-03033-3","journal-title":"Nat Med"},{"key":"6802_CR81","unstructured":"Mori T (2025) Diabetes subtyping for precision medicine \u2013 from practical implementation to methodological challenges (Doctoral dissertation). Available from https:\/\/katalog.ulb.hhu.de\/Record\/9947786537706443. Accessed 8 April 2026"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06802-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06802-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:16:31Z","timestamp":1788441391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06802-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":81,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["6802"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06802-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parts of this work are based on TM\u2019s PhD thesis [\n                      \n                      ]. Figure\n                      \n                      has been adapted and parts of the introduction and discussion section of the PhD thesis have been reused.","order":1,"name":"Ethics","label":"Acknowledgements","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The German Diabetes Center is funded by the German Federal Ministry of Health and the Ministry of Culture and Science of the state of North Rhine-Westphalia. The German Center for Diabetes Research is funded by the German Federal Ministry of Education and Research. JMD and PC are supported by a Wellcome Trust Early-Career Award (227070\/Z\/23\/Z) and the NIHR Exeter Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. TM is supported by the EASD mentorship programme. CH was supported by a grant from Horizon Europe (Intercept-T2D, 101095433). Neither of these funders had any role in the design, execution, analyses, interpretation of data or decision to submit results in this study. In particular, the research reported here received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The sole responsibility for the content of this publication lies with the authors.","order":2,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"CH is Reviews Editor for\n                      Diabetologia\n                      . JMD received an honorarium from Abbott. OK received honoraria for biostatistical education from Berlin-Chemie. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"TM conceptualised the review, prepared the visualisations, wrote the first draft and edited and reviewed the manuscript. CH, PC, and JMD contributed substantially to the conceptualisation of the review and to data interpretation, and reviewed it critically for important intellectual content. OK contributed substantially to the conceptualisation of the review and to data interpretation, reviewed it critically for important intellectual content, and provided supervision. All authors gave final approval of this version to be published. TM is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}